Safety Assessment of an Experimental Therapeutic and Prophylactic Anti-Cholera Agent in a Cell Culture Model

The study aimed to evaluate the safety of an experimental anti-cholera agent based on bacteriophages, enterosorbents, and specific immunoglobulins. The cytotoxic effects of various formulations of this therapeutic/prophylactic agent and its individual components (immunoglobulins, chinosol, pectin, and Polysorb) was studied using CHO-K1 (Chinese hamster ovary) and HuTu 80 (human duodenal adenocarcinoma) cell line models. Immunoglobulins, pectin, and the preservative chinosol were found to induce cytoplasmic vacuolization, along with cell rounding and death in both cell lines. Conversely, Polysorb MP and cholera bacteriophages did not cause similar changes. Based on the experimental findings, the optimal composition for the new experimental therapeutic/prophylactic agent against cholera was determined: Polysorb-MP, cholera bacteriophages (Rostov-13+Rostov-M3), and specific immunoglobulins, which is a non-toxic and safe formulation.

1. Aleksanina N.V., Moiseeva O.V. Eksperimental'noe izuchenie effektivnosti sovmestnogo lechebnogo dejstviya laktoglobulina i bakteriofaga sal'monelleznogo [Experimental study of the effectiveness of the combined therapeutic action of lactoglobulin and salmonella bacteriophage]. Infekciya i immunitet [Infection and immunity]. 2017;7(3):297–302. (In Russian). DOI: 10.15789/2220-7619-2017-3-297-302.

2. Aslanov B.I. Bakteriofagi — effektivnye antibakterial'nye sredstva v usloviyah global'noj ustojchivosti k antibiotikam [Bacteriophages — effective antibacterial agents in the context of global antibiotic resistance]. Medicinskij sovet [Medical Council]. 2015;13:106–109. (In Russian).

3. Briskin B.S., Demidov D.A. Evolyuciya enetrosorbcii v lechenii hirurgicheskogo endotoksikoza [Evolution of enterosorption in the treatment of surgical endotoxicosis] Mezhdunarodnyj medicinskij zhurnal [International medical journal]. 2004;4. (In Russian).

4. Zaharenko S.M. Bakteriofagi: Sovremennye aspekty primeneniya, perspektivy na budushchee [Modern aspects of application, prospects for the future] Medicinskij sovet [Medical Council]. 2013;10:72–74. (In Russian).

5. Litusov N.V. Vozbuditel' holery. Illyustrirovannoe uch. posob. [The causative agent of cholera. Illustrated textbook]. Ekaterinburg: GBOU VPO UGMA Publ., 2013:52. (In Russian).

6. Mazankova L.N., Pavlova A.A. Sovershenstvovanie patogeneticheskoj terapii ostryh kishechnyh infekcij u detej [Improving pathogenetic therapy of acute intestinal infections in children]. Detskie infekcii [Childhood infections]. 2006;4:67–69. (In Russian).

7. MUK 4.2.3745-22. Metody laboratornoj diagnostiki holery. Metodicheskie ukazaniya [Methods of laboratory diagnostics of cholera: Guidelines]. Moscow: Centrmag Publ., 2023:84. (In Russian).

8. Nikolaev V.G. Enterosorbciya: sostoyanie voprosa i perspektivy na budushchee [Enterosorption: the state of the art and future prospects]. Bulletin of Problems of Biology and Medicine. 2007;4:71–77. (In Russian).

9. Novokshonov A.A., Sokolova N.V., Berezhkova T.V., Saharova A.A. Klinicheskaya effektivnost' novogo enterosorbenta v kompleksnoj terapii infekcij virusnoj etiologii u detej [Clinical efficacy of a new enterosorbent in the complex therapy of viral infections in children]. Lechashchij vrach [Doctor therapist]. 2009;78–80. (In Russian).

10. Ovchinnikova M.V., Islyaeva M.N., Nikolaev V.G., Bardahivskaya K.I., Nikiforov A.K. Ocenka funkcional'noj aktivnosti specificheskogo protivoholernogo enterosorbenta [Evaluation of the functional activity of a specific anti-cholera enterosorbent]. Problemy osobo opasnyh infekcij [Problems of especially dangerous infections]. 2015;(2):83–86. (In Russian). DOI: 10.21055/0370-1069-2015-2-83-86.

11. Ovchinnikova M.V., Kireev M.N., Nikiforov A.K. Sorbcionnye svojstva polimernogo enterosorbenta i ego specificheskogo modifikanta v model'nyh rastvorah holernogo toksina in vitro [Sorption properties of a polymeric enterosorbent and its specific modifier in model solutions of cholera toxin in vitro]. Problemy osobo opasnyh infekcij [Problems of especially dangerous infections]. 2014;4:71–74. (In Russian)].

12. Permitina M.I., Popilov A.N., Ratnikova L.I. Effektivnost' enterosorbentov pri ostryh kishechnyh infekciyah [Efficiency of enterosorbents in acute intestinal infections]. Vrach [Doctor]. 2007;7:36–37. (In Russian).

13. Pogozhova M.P., Gaevskaya N.E., Tyurina A.V., Anoprienko A.O. Sozdanie kollekcii fagov patogennyh vibrionov i eyo primenenie v diagnosticheskih i profilakticheskih celyah [Creation of a collection of pathogenic vibrio phages and its use for diagnostic and prophylactic purposes]. Vestnik biotekhnologii i fiziko-himicheskoj biologii im. Yu.A. Ovchinnikova [Bulletin of Biotechnology and Physical-Chemical Biology named after Yu.A. Ovchinnikov]. 2023;19(3):37–45. (In Russian).

14. Tyurina A.V., Gaevskaya N.E., Ivanova I.A., Filippenko A.V., Omel'chenko N.D., Trufanova A.A., Pogozhova M.P., Anoprienko A.O., Sizova Yu.V., Pasyukova N.I. Ocenka effektivnosti ispol'zovaniya holernyh bakteriofagov dlya profilaktiki eksperimental'noj holery [Evaluation of the effectiveness of using cholera bacteriophages for the prevention of experimental cholera]. Problemy osobo opasnyh infekcij [Problems of especially dangerous infections]. 2024;2:193–195. (In Russian).

15. Tyurina A.V., Gaevskaya N.E., Pogozhova M.P., Anoprienko A.O. Izuchenie biologicheskih i geneticheskih svojstv holernyh bakteriofagov, vhodyashchih v sostav eksperimental'nogo profilakticheskogo preparata [Study of biological and genetic properties of cholera bacteriophages included in the experimental prophylactic drug]. Sovremennye problemy epidemiologii, mikrobiologii i gigieny: Mat-ly XIII Vseross. nauch.-prakt. konf. molodyh uchenyh i specialistov Rospotrebnadzora [Modern problems of epidemiology, microbiology and hygiene: Proceedings of the XIII All-Russian scientific and practical conference of young scientists and specialists of Rospotrebnadzor]. Ed. by A.Yu. Popova. Ekaterinburg: FBUN EMNC POZRPP Rospotrebnadzora, 2021:317–319. (In Russian).

16. Freshni R.Ya. Kul'tura zhivotnyh kletok. Prakt. ruk-vo. [Animal Cell Culture. A Practical Guide]. Transl. from Engl. from the 5th English edition by Yu.N. Khomyakov, T.I.Khomyakova. Binom. Laboratoriya znanij. 2018:691. (In Russian).

17. Butler S.M., Camilli A. Both chemotaxis and net motility greatly influence the infectivity of Vibrio cholera. Proc. Natl Acad. Sci. USA. 2004;101(14):5018–5023. DOI: 10.1073/pnas.0308052101.

18. Chan B.K., Turner P.E., Kim S., Mojibian H.R., Elefteriades J.A., Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evolution, medicine, and public health. 2018;1:60–66. DOI: 10.1093/emph/eoy005.

19. Charles R.C., Kelly M., Tam J.M., Akter A., Hossain M., Islam K., Biswas R., Kamruzzaman M., Chowdhury F., Khan A.I., Leung D.T., Weil A., LaRocque R.C., Bhuiyan T.R., Rahman A., MayoSmith L.M., Becker R.L., Vyas J.M., Faherty C.S., Nickerson K.P., Giffen S., Ritter A.S., Waldor M.K., Xu P., Kováč P., Calderwood S.B., Kauffman R.C., Wrammert J., Qadri F., Harris J.B., Ryan E.T. Humans surviving cholera develop antibodies against Vibrio cholerae O-Specific polysaccharide that inhibit pathogen motility. mBio. 2020;11(6):e02847-20. DOI: 10.1128/mBio.02847-20.

20. Jasion V.S., Burnett B.P. Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans. Nutr. J. 2015;14:22. DOI: 10.1186/s12937-015-0010-7.

21. Lee L., Samardzic K., Wallach M., Frumkin L.R., Mochly-Rosen D. Immunoglobulin Y for potential diagnostic and therapeutic applications in infectious diseases. Front. Immunol. 2021;12:696003. DOI: 10.3389/fimmu.2021.696003.

22. Liu Z., Miyashiro T., Tsou A., Hsiao A., Goulian M., Zhu J. Mucosal penetration primes Vibrio cholerae for host colonization by repressing quorum sensing. Proc. Natl Acad. Sci. USA. 2008;105(28):9769–9774. DOI: 10.1073/pnas.0802241105.

23. Okada K., Roobthaisong A., Hamada S. Flagellarelated gene mutations in Vibrio cholerae during extended cultivation in nutrient-limited media impair cell motility and prolong culturability. mSystems. 2023;8(5):e0010923. DOI: 10.1128/msystems.00109-23.

24. Onsea J., Soentjens P., Djebara S., Merabishvili M., Depypere M., Spriet I., Metsemakers W.J. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11(10):891. DOI: 10.3390/v11100891.

25. Pant N., Marcotte H., Brüssow H., Svensson L, Hammarström L. Effective prophylaxis against rotavirus diarrhea using a combination of Lactobacillus rhamnosus GG and antibodies. BMC Microbiol. 2007;7:86. DOI: 10.1186/1471-2180-7-86.

26. Rahman S., Van Nguyen S., Icatlo F.C. Jr., Umeda K., Kodama Y. Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases. Hum. Vaccin. Immunother. 2013;9(5):1039–1048. DOI: 10.4161/hv.23383.

27. Reilly R.M., Domingo R. & Sandhu J. Oral Delivery of Antibodies.Clin. Pharmacokinet.1997;32(4):313-323. DOI: 10.2165/00003088-199732040-00004.

28. Yen M., Cairns L.S., Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nature communications. 2017;8:14187. DOI: 10.1038/ncomms14187.